Cambridge Healthtech Institute & Bio-IT World Announces Program for Its 13th Annual Structure-Based Drug Design Conference, June 19-21, 2013, Boston, MA
Featuring Keynote from Aileron Therapeutics’ Tomi Sawyer
Needham, MA, February 16, 2013 --(PR.com)-- Cambridge Healthtech Institute (CHI) & Bio-IT World released today the complete agenda for the 13th annual Structure-Based Drug Design conference taking place June 19-21, 2013 at the Revere Hotel in Boston, MA.
The meeting serves as the “original” conference for the structure-based design community for industry and academic practitioners where delegates will learn about developments in in silico technology, as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. Examples of successful applications of such technology approaches to genome-to-drug lead investigations will also be discussed.
“I look forward to a great event this year," notes CHI Conference Director, Ming Guo. “I am inspired by the ambitious work from researchers in the SBDD field. CHI & Bio-IT World is honored the industry turns to us every year to organize this conference.”
This event boasts an impressive line-up of leading industry experts including a keynote presentation by Tomi Sawyer, Ph.D., CSO, SVP, Discovery & Innovative Technologies, Aileron Therapeutics. Dr. Sawyer’s presentation, entitled “Drugging the Undruggable: Transforming Nature's α-Helix into Breakthrough Medicines,” will take place on Thursday, June 20. As a case study, advancements in stapled peptide technology to transform Nature’s α-helix into breakthrough medicines will be presented.
The International Society for Computational Biology (ISCB) has endorsed its support as a sponsoring society. Due to the overwhelmingly popularity of the Structure-Based Drug Design event, CHI will once again co-locate its Next-Gen Kinase Inhibitors conference to run June 17-19. This gives delegates the unique opportunity to connect with the kinase community and attend the Structure-Based Drug Design event by obtaining an all access, discounted pass.
Early registration discounts will be offered until March 22, 2013. For more details, visit healthtech.com/sbd.
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.
Writers and editors are invited to attend. To request a press pass, contact Lisa Scimemi at tfielding@healthtech.com.
About Cambridge Healthtech Institute (chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
About Bio-IT World: (www.bio-itworld.com)
Part of the Cambridge Healthtech Institute Media Group (chimediagroup.com), Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Through a variety of sources including, www.Bio-ITWorld.com, Weekly Update Newsletter and the Bio-IT World News Bulletins, Bio-IT World is a leading source of news and opinion on technology and strategic innovation in the life sciences, including drug discovery, development.
Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
The meeting serves as the “original” conference for the structure-based design community for industry and academic practitioners where delegates will learn about developments in in silico technology, as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. Examples of successful applications of such technology approaches to genome-to-drug lead investigations will also be discussed.
“I look forward to a great event this year," notes CHI Conference Director, Ming Guo. “I am inspired by the ambitious work from researchers in the SBDD field. CHI & Bio-IT World is honored the industry turns to us every year to organize this conference.”
This event boasts an impressive line-up of leading industry experts including a keynote presentation by Tomi Sawyer, Ph.D., CSO, SVP, Discovery & Innovative Technologies, Aileron Therapeutics. Dr. Sawyer’s presentation, entitled “Drugging the Undruggable: Transforming Nature's α-Helix into Breakthrough Medicines,” will take place on Thursday, June 20. As a case study, advancements in stapled peptide technology to transform Nature’s α-helix into breakthrough medicines will be presented.
The International Society for Computational Biology (ISCB) has endorsed its support as a sponsoring society. Due to the overwhelmingly popularity of the Structure-Based Drug Design event, CHI will once again co-locate its Next-Gen Kinase Inhibitors conference to run June 17-19. This gives delegates the unique opportunity to connect with the kinase community and attend the Structure-Based Drug Design event by obtaining an all access, discounted pass.
Early registration discounts will be offered until March 22, 2013. For more details, visit healthtech.com/sbd.
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.
Writers and editors are invited to attend. To request a press pass, contact Lisa Scimemi at tfielding@healthtech.com.
About Cambridge Healthtech Institute (chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
About Bio-IT World: (www.bio-itworld.com)
Part of the Cambridge Healthtech Institute Media Group (chimediagroup.com), Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Through a variety of sources including, www.Bio-ITWorld.com, Weekly Update Newsletter and the Bio-IT World News Bulletins, Bio-IT World is a leading source of news and opinion on technology and strategic innovation in the life sciences, including drug discovery, development.
Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
Contact
Cambridge Healthtech Institute
James Prudhomme
781-972-5400
www.chicorporate.com
James Prudhomme
781-972-5400
www.chicorporate.com
Contact
Categories